Bone Abstracts

Introduction: Teriparatide is a potent anabolic drug that has demonstrated efficacy on fracture risk reduction in women with severe postmenopausal osteoporosis. Denosumab, designed to inhibit RANKL (RANK ligand), is a fully human MAB for the treatment of osteoporosis. BMD changes, measured by DXA, is an established tool for monitoring the effects of anti-osteoporotic therapy. Our purpose is to compare teriparatide vs denosumab efficacy on hip BMD variations, in postmenopausal ...

Introduction: Denosumab, a fully human monoclonal antibody to RANK ligand, effectively reduces bone resorption by inhibiting RANK-L binding to RANK. We aimed to evaluate the efficacy of denosumab in post-menopausal women, by monitoring the evolution of different parameters of bone health: T-score, morphometry, osteocalcin and β-Ctx.Methods: A 34 women with severe postmenopausal osteoporosis, characterized by multiple vertebral fractures wer...